oxymetazoline has been researched along with Rhinitis, Allergic, Nonseasonal in 13 studies
Oxymetazoline: A direct acting sympathomimetic used as a vasoconstrictor to relieve nasal congestion. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1251)
oxymetazoline : A member of the class of phenols that is 2,4-dimethylphenol which is substituted at positions 3 and 6 by 4,5-dihydro-1H-imidazol-2-ylmethyl and tert-butyl groups, respectively. A direct-acting sympathomimetic with marked alpha-adrenergic activity, it is a vasoconstrictor that is used (generally as the hydrochloride salt) to relieve nasal congestion.
| Excerpt | Relevance | Reference |
|---|---|---|
| "105 patients collected from chronic simple rhinitis, chronic hypertrophic rhinitis and perennial allergic rhinitis were treated with daphnlin spray (daphnlin group) or ephedrine spray (ephedrine group)." | 3.70 | [The curative effect of daphnlin spray on treating rhinitis]. ( Huang, X; Tan, H; Yue, J, 1999) |
| "The purpose of this review is to present data on nasal reactivity to methacholine, histamine and allergen in normal subjects, patients with common colds, perennial rhinitis and hay-fever." | 3.66 | Nasal reactivity in rhinitis. ( Borum, P; Brofeldt, S; Grønborg, H; Mygind, N, 1983) |
| "Oral prednisone pretreatment significantly reduced the mean of each subject's peak late-phase concentration of both MBP (30." | 2.66 | Major basic protein and eosinophil-derived neurotoxin concentrations in nasal-lavage fluid after antigen challenge: effect of systemic corticosteroids and relationship to eosinophil influx. ( Bascom, R; Dunnette, S; Gleich, GJ; Lichtenstein, LM; Naclerio, RM; Pipkorn, U; Proud, D, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (15.38) | 18.7374 |
| 1990's | 4 (30.77) | 18.2507 |
| 2000's | 2 (15.38) | 29.6817 |
| 2010's | 5 (38.46) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, W | 1 |
| Zhou, L | 1 |
| Zeng, Q | 1 |
| Luo, R | 1 |
| Luong, A | 1 |
| Cheung, EJ | 1 |
| Citardi, MJ | 1 |
| Batra, PS | 1 |
| Baroody, FM | 1 |
| Brown, D | 1 |
| Gavanescu, L | 1 |
| DeTineo, M | 1 |
| Naclerio, RM | 2 |
| Keiser, PB | 1 |
| Nelson, MR | 1 |
| Wandalsen, GF | 1 |
| Mendes, AI | 1 |
| Solé, D | 1 |
| Yue, J | 1 |
| Huang, X | 1 |
| Tan, H | 1 |
| Borum, P | 1 |
| Grønborg, H | 1 |
| Brofeldt, S | 1 |
| Mygind, N | 1 |
| Ticoll, B | 1 |
| Shugar, G | 1 |
| Ferguson, BJ | 1 |
| Paramaesvaran, S | 1 |
| Rubinstein, E | 1 |
| Willsie, SK | 1 |
| Selner, JC | 1 |
| Koepke, JW | 1 |
| Staudenmayer, H | 1 |
| Dolen, WK | 1 |
| Glover, GC | 1 |
| Linzmayer, MI | 1 |
| Mooney, JJ | 1 |
| Wiener, MB | 1 |
| Lau, SK | 1 |
| Wei, WI | 1 |
| Van Hasselt, CA | 1 |
| Sham, CL | 1 |
| Woo, J | 1 |
| Choa, D | 1 |
| Engzell, UC | 1 |
| Bascom, R | 1 |
| Pipkorn, U | 1 |
| Proud, D | 1 |
| Dunnette, S | 1 |
| Gleich, GJ | 1 |
| Lichtenstein, LM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Combination of Intranasal Steroid/Oxymetazoline Leads to Faster Relief of Nasal Congestion Without Inducing Rhinitis Medicamentosa[NCT00584987] | Phase 4 | 64 participants (Actual) | Interventional | 2007-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The Rhinoconjunctivitis Quality-of-Life Questionnaire (RQLQ) has 28 questions and focusses on 7 domains that may be significantly impaired in participants with seasonal allergic rhinoconjunctivitis: sleep impairment, non-nasal symptoms, practical problems, nasal symptoms, eye symptoms, activity limitations, and emotional difficulty. The RQLQ score is the mean of all 28 responses and the individual domain scores are the means of the items in those domains. RQLQ scores range from 0-6, with a higher score indicating more significant impairment. (NCT00584987)
Timeframe: assessed 2 weeks after initiation of treatment regimen
| Intervention | units on a scale (Mean) |
|---|---|
| Placebo FF + Placebo OXY | 2.20 |
| FF + Placebo OXY | 2.03 |
| Placebo FF + OXY | 2.11 |
| FF + OXY | 1.62 |
The Rhinoconjunctivitis Quality-of-Life Questionnaire (RQLQ) has 28 questions and focusses on 7 domains that may be significantly impaired in participants with seasonal allergic rhinoconjunctivitis: sleep impairment, non-nasal symptoms, practical problems, nasal symptoms, eye symptoms, activity limitations, and emotional difficulty. The RQLQ score is the mean of all 28 responses and the individual domain scores are the means of the items in those domains. RQLQ scores range from 0-6, with a higher score indicating more significant impairment. (NCT00584987)
Timeframe: assessed 4 weeks after initiation of treatment regimen
| Intervention | units on a scale (Mean) |
|---|---|
| Placebo FF + Placebo OXY | 1.75 |
| FF + Placebo OXY | 1.37 |
| Placebo FF + OXY | 1.85 |
| FF + OXY | 1.26 |
The Rhinoconjunctivitis Quality-of-Life Questionnaire (RQLQ) has 28 questions and focusses on 7 domains that may be significantly impaired in participants with seasonal allergic rhinoconjunctivitis: sleep impairment, non-nasal symptoms, practical problems, nasal symptoms, eye symptoms, activity limitations, and emotional difficulty. The RQLQ score is the mean of all 28 responses and the individual domain scores are the means of the items in those domains. RQLQ scores range from 0-6, with a higher score indicating more significant impairment. (NCT00584987)
Timeframe: assessed 6 weeks after initiation of treatment regimen
| Intervention | units on a scale (Mean) |
|---|---|
| Placebo FF + Placebo OXY | 1.85 |
| FF + Placebo OXY | 1.83 |
| Placebo FF + OXY | 2.03 |
| FF + OXY | 1.55 |
The Rhinoconjunctivitis Quality-of-Life Questionnaire (RQLQ) has 28 questions and focusses on 7 domains that may be significantly impaired in participants with seasonal allergic rhinoconjunctivitis: sleep impairment, non-nasal symptoms, practical problems, nasal symptoms, eye symptoms, activity limitations, and emotional difficulty. The RQLQ score is the mean of all 28 responses and the individual domain scores are the means of the items in those domains. RQLQ scores range from 0-6, with a higher score indicating more significant impairment. (NCT00584987)
Timeframe: assessed at baseline
| Intervention | units on a scale (Mean) |
|---|---|
| Placebo FF + Placebo OXY | 3.07 |
| FF + Placebo OXY | 3.25 |
| Placebo FF + OXY | 2.99 |
| FF + OXY | 2.60 |
The severity of nasal congestion was recorded in the morning (reflective of symptoms overnight) and evening (reflective of daytime symptoms) on a 0 to 3 scale. The total nasal congestion symptom score was obtained by adding the symptoms obtained on all 28 days of treatment. Values for this outcome are in the range of 0 to 168 (i.e., 6 x 28). Congestion scores increase with congestion severity (i.e., higher numbers correspond to worse congestion). (NCT00584987)
Timeframe: 28 days of treatment
| Intervention | units on a scale (Median) |
|---|---|
| Placebo FF + Placebo OXY | 94 |
| FF + Placebo OXY | 70 |
| Placebo FF + OXY | 75 |
| FF + OXY | 68 |
Nasal peak inspiratory flow (NPIF) is a physiological measure of nasal airflow which is particularly sensitive to nasal valve collapse. NPIF was measured objectively in liters per minute with an In-Check Peak Inspiratory FlowMeter (Ferraris Medical Inc, Orchard Park, NY). Subjects obtained 3 readings every morning and every evening and recorded the best flow measured. The morning and evening NPIF measurements were summed for days 2 through 28 of the treatment cycle, yielding the total NPIF outcome measure. NPIF scores increase with air flow quality (i.e., higher NPIF values are indicative of better nasal air flow). (NCT00584987)
Timeframe: days 2 through 28 of the treatment cycle
| Intervention | liters per minute (Median) |
|---|---|
| Placebo FF + Placebo OXY | 5240 |
| FF + Placebo OXY | 5680 |
| Placebo FF + OXY | 4485.5 |
| FF + OXY | 5520 |
1 review available for oxymetazoline and Rhinitis, Allergic, Nonseasonal
| Article | Year |
|---|---|
Improved strategies and new treatment options for allergic rhinitis.
Topics: Administration, Intranasal; Beclomethasone; Cromolyn Sodium; Histamine H1 Antagonists; Humans; Immun | 2002 |
6 trials available for oxymetazoline and Rhinitis, Allergic, Nonseasonal
| Article | Year |
|---|---|
Combination of mometasone furoate and oxymetazoline for the treatment of adenoid hypertrophy concomitant with allergic rhinitis: A randomized controlled trial.
Topics: Adenoids; Case-Control Studies; Child; Demography; Female; Humans; Hypertrophy; Male; Mometasone Fur | 2017 |
Oxymetazoline adds to the effectiveness of fluticasone furoate in the treatment of perennial allergic rhinitis.
Topics: Administration, Intranasal; Adult; Androstadienes; Anti-Inflammatory Agents; Double-Blind Method; Dr | 2011 |
A study of the effect of nasal steroid sprays in perennial allergic rhinitis patients with rhinitis medicamentosa.
Topics: Adult; Anti-Inflammatory Agents; Budesonide; Double-Blind Method; Female; Humans; Male; Middle Aged; | 2001 |
Assessment of nasal patency by rhinoscopic measurement of cross sectional nasal airway area: correlation with subjective nasal symptoms.
Topics: Adult; Endoscopy; Ephedrine; Female; Humans; Male; Nasal Cavity; Nasal Decongestants; Oxymetazoline; | 1991 |
A clinical comparison of budesonide nasal aerosol, terfenadine and a combined therapy of budesonide and oxymetazoline in adult patients with perennial rhinitis.
Topics: Adolescent; Adult; Aerosols; Aged; Benzhydryl Compounds; Bronchodilator Agents; Budesonide; Double-B | 1990 |
Major basic protein and eosinophil-derived neurotoxin concentrations in nasal-lavage fluid after antigen challenge: effect of systemic corticosteroids and relationship to eosinophil influx.
Topics: Blood Proteins; Cell Movement; Double-Blind Method; Eosinophil Granule Proteins; Eosinophil-Derived | 1989 |
6 other studies available for oxymetazoline and Rhinitis, Allergic, Nonseasonal
| Article | Year |
|---|---|
Evaluation of optical rhinometry for nasal provocation testing in allergic and nonallergic subjects.
Topics: Administration, Intranasal; Adult; Allergens; Female; Histamine; Humans; Oxymetazoline; Rhinitis, Al | 2010 |
Baseline differences explain the apparent benefits of combining oxymetazoline with intranasal corticosteroids.
Topics: Androstadienes; Anti-Inflammatory Agents; Female; Humans; Male; Nasal Decongestants; Oxymetazoline; | 2011 |
Correlation between nasal resistance and different acoustic rhinometry parameters in children and adolescents with and without allergic rhinitis.
Topics: Adolescent; Airway Resistance; Case-Control Studies; Child; Humans; Nasal Cavity; Nasal Decongestant | 2012 |
[The curative effect of daphnlin spray on treating rhinitis].
Topics: Administration, Inhalation; Adolescent; Adult; Ephedrine; Female; Humans; Male; Middle Aged; Nasal D | 1999 |
Nasal reactivity in rhinitis.
Topics: Allergens; Animals; Common Cold; Female; Histamine; Humans; Male; Methacholine Chloride; Methacholin | 1983 |
Paranoid psychosis induced by oxymetazoline nasal spray.
Topics: Administration, Intranasal; Adult; Humans; Male; Oxymetazoline; Paranoid Disorders; Rhinitis, Allerg | 1994 |